{
  "pmid": "41450930",
  "title": "Outcomes with frontline immune checkpoint inhibitors among individuals with ",
  "abstract": "Oncogenic  We retrospectively analyzed patients with  Among 122 individuals, 54 had Class I and 68 had non-Class I mutations. For Class I mutations, ICIs yielded a PFS of 9.2 months and OS of 42.2 months, representing a significant OS advantage over chemotherapy-alone (22.2 months;  ICIs appear effective in ",
  "disease": "lung cancer"
}